0.17
+2.98%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arcadia Biosciences
From its filings with the US Securities and Exchange Commission
Arcadia Biosciences is based in Dallas, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RKDA. The SEC classifies its business as crude petroleum & natural gas. In the fiscal year to 31 December 2025, it reported revenue of $4.9m and a net loss of $2.3m. At that date it held total assets of $6.5m.
Arcadia has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Since acquiring the assets of Zola in May 2021, Arcadia has provided consumers with a way to rehydrate, reset, and reenergize with Zola coconut water products. Previously, Arcadia developed products, primarily in wheat, which it commercialized through the sale of food products, trait licensing and royalty agreements.
On December 4, 2024, Arcadia, Roosevelt Resources LP (“Roosevelt” or the “Partnership”) and Elliott Roosevelt, Jr. and David A. Roosevelt, in their capacities as representatives of the limited partners of the Partnership entered into a Securities Exchange Agreement (as it may be amended from time to time, the “Exchange Agreement”) providing for the combination of the two companies in an all-stock transaction. Subject to the terms of the Exchange Agreement and to the satisfaction or waiver of the conditions set forth in the Exchange Agreement, at the closing of the transactions Arcadia agreed to issue shares of its common stock to the limited partners and to the sole member of the general partner of Roosevelt (together, the “Limited Partners”) in exchange for all of the limited partnership and other equity interests of Roosevelt (the “Exchange”). The Exchange Agreement, as amended, provided that upon completion of the Exchange, the Limited Partners and the Arcadia stockholders prior to the closing were to own 90% and 10%, respectively, of the shares of common stock of Arcadia immediately after the closing.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Consumer Staples
- Industry
- Food Products
- Listed since
- 15 May 2015
- Employees
- 8
- Website
- arcadiabio.com ↗
- Head office
- 5956 SHERRY LANE, DALLAS, TX
- Incorporated in
- DE
- Classification
- Crude Petroleum & Natural Gas
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Kevin ComcowichIndependent Chairman of the Board, since 2016$153,442
- Mr. Thomas SchaeferPresident, Chief Executive Officer, Interim Chief Financial Officer, since 2023$499,477
- Ms. Lilian MurrayIndependent Director$92,474
- Mr. Gregory WallerIndependent Director$90,974
- Ms. Amy YoderIndependent Director$88,974
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arcadia Biosciences develops nitrogen use efficiency traits for global crops like wheat and rice.
- The company has a pipeline of products in advanced development stages for food and feed markets.
- Arcadia's portfolio includes drought tolerance and salinity tolerance traits for crops in Africa and India.
Weaknesses
- Arcadia employs only 8 full-time employees, which is below the industry standard for biotech firms.
- The company's headquarters in Davis, California, limits its operational scale compared to larger competitors.
- Arcadia's IPO in 2015 has not led to significant market expansion or product launches.
Opportunities
- Arcadia can expand its presence in the United Arab Emirates and Canada for agricultural product distribution.
- The growing demand for water use efficiency traits in drought-prone regions offers new market opportunities.
- India's agricultural sector presents a significant opportunity for deploying salinity tolerance traits.
Threats
- Competition from larger biotech firms in the United States poses a threat to Arcadia's market share.
- The lack of a strong product portfolio in the European market increases vulnerability to regional competitors.
- Regulatory changes in the Food Products sector could impact Arcadia's trait development and market entry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.